Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Vascular On Track For 60% Growth In 2007

This article was originally published in The Gray Sheet

Executive Summary

Abbott's vascular business is on target to achieve growth of "at least 60%" this year following a strong first quarter that saw continued success of the firm's Xience V everolimus-eluting coronary stent outside of the United States, the company says

You may also be interested in...

Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA

Abbott Sells IVD, Point-Of-Care Diagnostics To GE For $8.13 Bil.

With GE's $8.13 billion cash purchase of Abbott Laboratories' core in vitro diagnostics unit Jan. 18, the corporate giant is betting it can accelerate growth in a business still recovering from protracted regulatory challenges in the U.S

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts